Skip to main content

Principal Investigator: Vimal Derebail, MD, MPH
Sponsor: Retrophin, Inc
Age Range: 12 to 75 years of age
Status: Enrolling

Purpose: To determine if long term treatment with sparsentan, a dual endothelin receptor and angiotensin receptor blocker,  is better at protecting the kidneys than an angiotensin receptor blocker (irbesartan) in patients with primary focal segmental glomerulosclerosis (FSGS).

Study Procedures: During visits, patients will undergo blood draw, urine collection, review of medications, vitals and answer to quality of life surveys.

Participation: Participants will have a screening visit. If a participant is already taking an angiotensin receptor blocker or similar medication, a washout period of 2 weeks not taking that drug will be requested before the start of the study drug administration at Week 0 visit. Visits will then occur every 2 weeks for the first 3 months then every 3 months for 2 years. Participants may not need to make any changes to their current immunosuppressive regimen.

For more information, please contact:

Anne Froment